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Abstract
Background: Management of patients with polypharmacy is challenging, and evidence for beneficial effects of
deprescribing interventions is mixed. This study aimed to investigate whether a patient-centred deprescribing
intervention of PCPs results in a reduction of polypharmacy, without increasing the number of adverse disease
events and reducing the quality of life, among their older multimorbid patients.
Methods: This is a cluster-randomised clinical study among 46 primary care physicians (PCPs) with a 12 months
follow-up. We randomised PCPs into an intervention and a control group. They recruited 128 and 206 patients if
≥60 years and taking ≥five drugs for ≥6 months. The intervention consisted of a 2-h training of PCPs, encouraging
the use of a validated deprescribing-algorithm including shared-decision-making, in comparison to usual care. The
primary outcome was the mean difference in the number of drugs per patient (dpp) between baseline and after
12 months. Additional outcomes focused on patient safety and quality of life (QoL) measures.
Results: Three hundred thirty-four patients, mean [SD] age of 76.2 [8.5] years participated. The mean difference in
the number of dpp between baseline and after 12 months was 0.379 in the intervention group (8.02 and 7.64; p =
0.059) and 0.374 in the control group (8.05 and 7.68; p = 0.065). The between-group comparison showed no
significant difference at all time points, except for immediately after the intervention (p = 0.002). There were no
significant differences concerning patient safety nor QoL measures.
Conclusion: Our straight-forward and patient-centred deprescribing procedure is effective immediately after the
intervention, but not after 6 and 12 months. Further research needs to determine the optimal interval of repeated
deprescribing interventions for a sustainable effect on polypharmacy at mid- and long-term. Integrating SDM in the
deprescribing process is a key factor for success.
Trial registration: Current Controlled Trials, prospectively registered ISRCTN16560559 Date assigned 31/10/2014.
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Background
Management of multimorbid patients, the majority of
whom are treated by primary care physicians (PCP), is
challenging [1–4]. A major issue in this predominantly
old population is polypharmacy, commonly defined as
the intake of five or more drugs per capita, which entails
the risk of adverse drug reactions [5–8]. This subse-
quently leads to an increase in morbidity [9, 10], hospital
admissions [11–13], health-related costs and ultimately,
the number of deaths [14–16].
Several clinical deprescribing tools and strategies for
different healthcare providers (pharmacists, physicians,
nurses) [17–25], mostly for the inpatient setting and
using computer-assisted decision aids, have been tested
[26]. The communication about patients’ needs and pref-
erences in the process of deprescribing is challenging
and a patient-centred approach, taking into account
these topics, is of utmost importance to enable safe and
effective deprescribing [27–31]. One of the first land-
mark trials using this approach by Garfinkel and Mangin
in 2010, introduced the Good Palliative-Geriatric Prac-
tice (GPGP) algorithm [32]. Studies with PCP-lead inter-
ventions in the primary care setting, including shared-
decision-making (SDM) and long-term, follow up are
still scarce.
According to previous studies of deprescribing effi-
ciency, the impact of these interventions on clinically
relevant endpoints, e.g. falls, use of health care facil-
ities, morbidity or mortality, is often small or even
nonexistent and varies [18, 19, 33, 34]. Furthermore,
complex deprescribing interventions are challenging
to implement in the primary care setting, e.g. due to
time restrictions or structural shortcomings [17, 35,
36]. Thus, there is a need for effective and feasible
approaches to reduce inappropriate polypharmacy in
primary care, with an emphasis on acceptance and
implementation into routine care [28, 37]. Therefore
we designed a foreshorten, paper-based intervention
to tackle two of the major barriers in the primary
care setting especially common in Switzerland, time
and lack of uniform digital solutions in practices [38,
39]. This study aimed to investigate whether a
patient-centred deprescribing intervention of GPs re-
sults in a reduction of polypharmacy, without increas-
ing the number of adverse disease events and




We conducted a two-armed, cluster-randomised, clinical
trial in Swiss primary care practices from January 1,
2015, to June 1, 2017.
Participants
We invited German-speaking, officially registered PCPs
working in ambulatory primary care practices from
northern Switzerland stepwise by canton (region) by let-
ter to participate. We stratified enrolled PCPs as clusters
by practice to avoid contamination. Approximately one-
half of the clusters were randomised to the intervention
(n = 22) and one-half to control group (n = 24). After
randomisation PCPs received the allocated training ses-
sion (see below), before identifying eligible patients by
reviewing their daily patient list. We asked PCPs to
recruit a maximum of 15 patients. They received an ex-
pense allowance of 100 CHF per recruited patient.
PCPs continuously recruited patients independent of
race or ethnicity whenever they fulfilled the following
criteria: a) cared for by one of the participating PCPs b)
≥60 years of age c) ≥ 5 chronic drugs for ≥ 6 months d)
capable of judgement. Enrolled patients were blinded to
the study arm insofar as blinding was guaranteed by ran-
domisation on PCP level. See the study flowchart to
visualise the patient selection process (Fig. 1).
Intervention description
Intervention on PCP level (training session)
In the intervention group, PCPs received a lecture
(length: 2 h) on polypharmacy and trained the use of our
deprescribing-algorithm and to discuss its results with
their patients (SDM). This intervention could take place
immediately after obtaining informed consent or in a
separate consultation. We adapted the Good Palliative-
Geriatric Practice (GPGP) algorithm, which is a depre-
scribing tool developed for and tested in a geriatric
setting [32]. Adaption meant simplifying from six to four
key questions to answer. See Fig. 2 for details. We
previously pilot-tested this adapted algorithm to assess
its feasibility and practicability in the primary care
setting [40].
In the control group, PCPs received a general lecture
(length: 2 h) on multimorbidity and instructions for col-
lecting usual care data. For blinding purposes, we in-
formed PCPs that the study purpose was to investigate
best practices for physician-patient communication.
Intervention on patient-level (during the first encounter)
After obtaining informed consent from the patient, a
practice-nurse, or the PCP created a list of the patient’s
current medication. Then, the PCP defined the four
main diagnoses and a list of the four most important
complaints in consensus with the patient, to facilitate
prioritisation of treatment goals. PCPs in the interven-
tion group then decided for every single drug listed if it
was appropriate for the patient, according to the algo-
rithm (Fig. 2).
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Based on these questions, the PCP made a recommen-
dation for each drug. In an SDM procedure that
followed the PCPs recommendation, the PCP and pa-
tient then decided together what changes to implement,
always with the option to restart if symptoms should in-
crease or if the disease should deteriorate. PCPs used a
checklist, including many individual steps to guide the
first consultation (see Additional file 1 for details). The
SDM procedure was guaranteed by the stepwise charac-
ter of the algorithm, including the task of SDM itself.
Time points and outcomes
Time points are defined as follows:
Pre-Intervention T0 (before the first consultation, pre-
viously also named baseline), Post-Intervention T1 (at
the end of the first consultation), after 6-Months T2, and
after 12-Months T3.
Primary outcome
Mean difference in the number of drugs per person
(DPP) between Pre-Intervention and after 12 months.
Secondary outcomes
Mean difference in the number of dpp between Pre-
Intervention and Post-Intervention
2.1 Mean difference in the number of dpp between
Pre-Intervention and after 6 months
2.2 Number of drugs with PCP’s recommendation to
change and what kind of change (either stopping,
dose change or alternative drug)
2.3 Frequency of discrepant decisions between PCP and
patient about the change of a drug, and therapeutic
groups of drugs patients were not willing to change
2.4 Number of dpp taken without the PCPs knowledge,
at Pre-Intervention
Fig. 1 Study flowchart. Randomisation on PCP level, patient recruitment and follow-up during the study
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2.5 Symptom scores, rates of hospitalisation, death and
unexpected clinical events
2.6 Quality of life rating by the patients at Pre-
Intervention, after 6 and 12 months
2.7 Time consumption due to the intervention, by the
practice nurse and by PCP
For further details, including interim analysis and stop-
ping guidelines, see study protocol [41].
Measures
PCPs and patients collected data on pre-coded paper
documents (Additional file 1) at the four-time points.
PCPs stored the codes identifying the individual patient
in their practice. Data transfer to the electronic database
was carried out and double-checked by two research
associates.
We categorised diagnoses according to an adapted ver-
sion of a classification system by van den Bussche et al.
[42] For coding of complaints we used ICPC-2 coding
[43] and for drugs the ATC code [44]. We compared
diagnosis and complaints as perceived by PCPs and pa-
tients based on ratings. (For details and results see [45]).
Patients reported QoL, as well as the symptom score of
the worst complaint on paper format all three consulta-
tions. We used three different tools to document QoL:
a) five-point Likert-scale ranging from − 2 to + 2, with
− 2 the worst possible, + 2, the best possible,
b) a visual analogue scale (VAS) ranging from 0 to 100
to document their current health status, with 0 the
worst possible, 100 the best possible, and
c) the “functional” EQ-5D-3L set of questions concern-
ing topics of mobility/activity, self-catering, general
Fig. 2 Deprescribing-algorithm. Deprescribing-algorithm used by the PCP in the intervention group
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activities, pain/physical complaints and fear/depres-
sion [46]. Patients reported symptoms on a scale ran-
ging from 0 (no symptoms) to 10 (worst symptoms
possible). We asked PCPs to report all hospitalisa-
tions and deaths as well as all other clinical events
they considered essential for our study on a pre-
coded paper form, on which more detailed informa-
tion on the events` character, the context and the
consequences were required, as well as the PCPs
probability estimate of the causal relationship be-
tween the previous deprescribing procedure and the
event. In case of drop- out, patients̀ data gathered so
far were computed.
Additionally, to those characteristics above, we col-
lected the following patient and PCP characteristics. For
patients: Age [years], sex (PCP classified), number of
drugs and living situation. For PCPs: Age [years], sex (in-
vestigator classified), working experience [years], type of
practice [single or group] and affiliation to physician
network [yes or no]. We used the web-based data man-
agement program SecuTrial® (version 5.0.1, 2016) [47].
We applied CONSORT guidelines for reporting of all
data and visualisation of study flow [48].
Statistical analysis
We randomised in blocks, making sure PCP’s from the
same practice were in the same group to prevent
contamination. Freely available software named
“randomization.com” was used [49].
We performed power calculations for the study’s pri-
mary outcome, with a power of 80%, a two-sided alpha-
error of 2.5%, a cluster effect of 2% [50], a standard error
of 2.8 and an assumed effect size of 0.8 dpp (based on
our pilot) [40] and an assumed drop-out rate of 10%.
For the descriptive analysis of PCPs’ and patients’
characteristics, we used frequencies and percentages
for categorical variables, and for continuous variables
means and standard deviation (SD) or median and
interquartile range (IQR). To compare groups with
categorical variables, we used the Chi-square test or
Fisher’s exact test. For comparison of groups and
times with continuous variables, we used Welch’s t-
test or Mann-Whitney-U test. We provided p-values
and 95% confidence intervals (95%-CI). We used the
statistical program R® Version 3.5 37.
As a sensitivity analysis, we calculated the deprescrib-
ing rate, defined as the proportion of the number of
drugs stopped at a given time point in relation to the
number of drugs at baseline, for each time point after
Pre-Intervention. We compared the rates between
groups using Chi-square test or Fisher’s exact test. The
distribution of drugs which were recommended to
change by the PCP and those with a patient’s agreement
to the recommendation was calculated.
Results
Mean age of the 334 included patients (128 intervention
group/ 206 control group) was 76.2 (SD 8.5) years, 136
(45.5%) females, taking 8.05 (SD 2.5) dpp, with no sig-
nificant differences between groups. Drop-out rates were
9.3% (31 of all patients), 6.0% (20 of all patients) due to
death and 3.3% (11 of all patients) due to the change of
attending PCP. Mean age of 46 participating PCPs was
49.4 (SD 9.3), 30 (65%) males, working for 13.6 (SD 9.7)
years in private practice. (For further details see Add-
itional file 2 and (25)) The main therapeutic drug classes
were cardiovascular (30% of all drugs), neurologic-
analgetic (15.6%) and anticoagulant (8.7%) drugs at
baseline. Rates of drugs stopped were 41.7% for cardio-
vascular, 14.8% for neurologic-analgetic and 8.3% for
anticoagulant drugs. For further details on drugs, see
Additional file 3.
The mean difference in the number of dpp between
Pre-Intervention and after 12months (primary outcome)
was 0.379 in the intervention group (8.02 at Pre-
Intervention and 7.64 after 12months; p = 0.059) and
0.374 in the control group (8.05 at Pre-Intervention and
7.68 after 12months; p = 0.065). For the time points Post-
Intervention and after 6 months, there was a significant
reduction in dpp in the intervention group (p = < 0.001
and 0.002). In the control group, there was no significant
change in the number of dpp over all time points. In the
between-group comparison, there was no significant dif-
ference at all time points, except for Post-Intervention
(p = 0.002) (Fig. 3). For further details, see Table 1.
The deprescribing rates at T2 and T3 were between
23.9 and 29.0% in the intervention group and between
14.0 and 21.5% in the control group (p < 0.001 for differ-
ence) (Additional file 4).
Intervention group PCPs recommended changes of
drugs in 209 (20.5%) of all 1019 drugs at baseline. In 170
(81.3%) of these 209 recommendations, patients imple-
mented a change. One hundred five drugs were stopped,
and 85 (81%) of them remained stopped after 12months.
On PCP level, the agreement of patients to the recom-
mended drug changes was 86% (weighted mean per
centre 0.858, SD 0.231) (Fig. 4).
PCPs reported that no drugs were taken without their
previous knowledge at Pre-Intervention. For more infor-
mation on drug classes that were stopped, restarted and
started due to a new indication, see Fig. 5 and
Additional file 5.
During the follow-up period, 43 (33.6%) of patients were
hospitalised in the intervention group compared to 54
(26.2%) in the control group (p = 0.32 for between-group
difference), and seven (5.5%) patients died in the
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intervention group compared to 13 (6.3%) in the control
group (p = .95 for between-group difference) See Table 2
for details.
Mean QoL values on 0–100 point scale at the three-
time points were between 65.9 and 67.2 for the interven-
tion group and between 65.0 and 69.0 for the control
group, with no significant difference between groups (p
from 0.270 to 0.383) and between time points. A signifi-
cant increase in the QoL value in the control group be-
tween baseline and after 12months (p = 0.025) was the
only exception. Mean QoL on Likert-scale, and functional
EQ-5D-3L showed no significant difference between time
points or groups. For further details, see Table 3.
Overall time consumption of PCPs and nurses during
the first consultation was 30.1 (SD 10.7) minutes in the
intervention and 27.1 (SD 13.84) minutes in the control
group (p = 0.066).
Discussion
In our study population of older community-dwelling
patients with polypharmacy, the use of a straight-
forward and patient-centred deprescribing procedure
was effective immediately after the intervention, but not
after 6 and 12months) compared to the control group
providing usual care. Clinical events, hospitalisations and
death rates, as well as QoL measures, were not signifi-
cantly different between groups at all time points.
Effectiveness over time
Our intervention resulted in a statistically significant im-
mediate reduction in the number of drugs per patient,
and 81% of all drugs stopped during the intervention
consultation remained stopped after 12 months.
However, the reduction in the total number of drugs
was not preserved over time due to new prescriptions.
A probable reason might be our study population of
old and multimorbid patients. As previously shown by
Lam and others, this population is at high risk for new
diseases, clinical events, hospitalisations and symptoms.
Almost two-thirds of all patients faced either a clinical
event or hospitalisation during the follow-up period,
leading to new drugs and multiple drugs changes [51–
53] (Table 2, Additional file 3). This natural course of
diseases and consecutive drug treatment may dilute the
overall impact of the intervention over time. As previ-
ously recommended by Dills et al., our results encourage
repeated deprescribing interventions to reach a sustain-
able mid- and long-term effect, [54].
Safety and quality of life
Whenever deprescribing interventions are carried out, it
is of utmost importance not to harm patients or deteri-
orate their QoL. As a non-inferiority safety measure, we
found no negative impact of the intervention on clinical
events, hospitalisations or deaths. Regarding QoL, result-
ing levels are in line with previously reported results in
multimorbid patients in the Swiss primary care setting
[55], but lower than those in the general population [32,
56–58]. Most importantly, the QoL results of the two
groups in our study did not differ statistically signifi-
cantly (Table 3)., thus reflecting that the deprescribing
intervention was not inferior to usual care regarding
QoL, i.e. did not lower the QoL of patients. Therefore
we can conclude that the PCPs have deprescribed appro-
priately, without taking the risk of clinical or subjective
deterioration of the patient.
Fig. 3 Mean number of drugs. Mean number of drugs in both groups during the study with CI (95%). X-axis = Mean number of drugs, y-axis =
Time. Time points: Pre-int = Pre-intervention, Post-int = Post-Intervention
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However, the functional EQ-5D-3L QoL score de-
creased in both groups, likely due to the natural loss of
function caused by ageing. (Table 3). As stated by Rick-
ert et al. in their latest paper, the fact, the reduction of
drugs did not increase harm to patients, can be seen as a
positive result in itself [59].
Importance of SDM
The results of our study emphasise that an individualised
approach and interaction with the patient is crucial for a
successful and sustainable deprescribing. We ensured in-
dividualisation and interaction with the patient, by mean
of addressing and prioritising patients’ subjective com-
plaints in addition to medical diagnosis. Furthermore,
we integrated SDM into the deprescribing algorithm.
Our finding that patients agreed to a drug change in
86% of drugs recommended to change (on PCP level)
indicates a high adherence towards the intervention, and
we believe that this mainly due to focus on SDM during
the deprescribing process. PCPs not only have frequent
patient consultations and thus windows of opportunity
to tackle polypharmacy together with their patient, but
are also highly trusted by patients, as previously reported
in a paper by our study group [60]. Mutual trust facili-
tates SDM procedures, resulting in more successful
deprescribing [29, 60–63]. Von Buedingen et al., also
using an SDM approach, reported a similar high adher-
ence of patients towards their initial decision [52, 64,
65]. Page et al. came to a similar conclusion in their ex-
tensive systematic review on the feasibility and effect of
deprescribing in older patients, highlighting the import-
ance of patient-specific individualised approaches such
as ours using SDM as the central mean of an interven-
tion [18].
Table 1 Mean number of drugs in both groups
Intervention group
mean dpp (95% CI)
Control group
mean dpp (95% CI)
Difference between groups
mean dpp (95% CI) P-value
Pre-Intervention (T0) 8.02 (7.59–8.46) 8.05 (7.71–8.40) −0.03 (− 0.59–0.53) 0.916
Post-Intervention (T1) 7.20 (6.81–7.60)a −0.85 (−1.38–0.32) 0.002
6months (T2) 7.54 (7.07–8.37) a 8.01 (7.56–8.37)b − 0.47 (− 1.07–0.12) 0.118
12months (T3) 7.64 (7.17–8.12) a 7.68 (7.32–8.00) b −0.04 (− 0.63–0.56) 0.906
The mean number of drugs per patient (DPP) at all four-time points and between-group differences. T0 = First consultation, before intervention, T1 = First
consultation, immediately after the intervention, T2 = Second consultation 6months later, T3 = Third consultation 12 months later. CI = 95% confidence interval, a)
p-values for the time point comparison within the intervention group: T1-T0, T2-T0 and T3-T0: < 0.001, 0.002 and 0.059. b) p-value for the time point comparison
within the control group: T2-T0 and T3-T0: 0.960 and 0.065
Fig. 4 Recommended drug changes and agreement. Number of drug changes recommend per primary care physician during the first
consultation (T0). This recommendation Red bar shows the number of drugs recommend for change by the primary care physician and the blue
bar shows the number of drugs on which the patient and the primary care physician agreed to proceed with the recommended change
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Barriers towards deprescribing
However, several psychological barriers are hindering a
minority of patients from implementing drug changes
[27, 66, 67]. We reported several reasons for a disagree-
ment of or our study patients with the recommendations
of PCP elsewhere [60]. The open discussion of depre-
scribing barriers is essential, to find solutions and to in-
crease the efficacy of the deprescribing interventions
[27]. This discussion and finding consent again is an in-
tegral part of the SDM process.
Time constraint is another major deprescribing barrier
[17, 27, 35]. Our consultation duration was twice as long
as an average encounter in the Swiss healthcare system,
probably reflecting the task of dealing with multimorbid
and complex patients, requiring more consultation time
compared to the average ambulatory care population
[68–70]. However, the duration did not differ signifi-
cantly between groups. We conclude that our straight-
forward study intervention itself did not require add-
itional time which is supporting the feasibility of the
intervention.
Another barrier is the fact that some PCPs may be
reluctant to use a paper-based or digital “stand-alone”
deprescribing algorithm. The integration of our pro-
cedure in existing electronic medical records and de-
cision aids remains a promising option for further
implementation while keeping in mind that this step
is challenging and might induce potential new bar-
riers [39, 59].
Strengths
First, to our knowledge, the 12months follow-up of this
study is among the longest in deprescribing research and
this setting. Second, we hardly selected our study popu-
lation, resulting in a population of patients mainly living
independently at home. Thus, thinking in terms of dis-
semination and public health impact, our findings may
help to deal with older outpatient PCP population with
polypharmacy.
Limitations
First, we cannot rule out a selection bias of PCPs with a
commitment for deprescribing and patient-centred com-
munication style above-average volunteering more fre-
quently for study participation. Otherwise, we believe
the trial findings are generalisable for older patients in
an industrialised outpatient primary care setting. Thus
one must always bear in mind that the primary care set-
ting is quite different between countries. Second, al-
though the cluster-randomisation performed on PCP
level resulted in an equal number of PCPs in both
groups, the number of patients in the two groups varied
noticeably, with fewer patients in the intervention group.
Fig. 5 Drug flow chart. Drug charges in the intervention group after a recommendation by the PCP was given








58 (45.3) 61 (29.6) 0.318
Hospitalisations
No. (%)
43 (33.6) 54 (26.2) 0.162
Deaths
No. (%)
7 (5.5) 13 (6.3) 0.954
The number of clinical events, hospitalisations, and deaths in both groups and
significance between groups
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Besides the fact that the protocol defined a maximum
number of patients per PCP but not a minimal one,
there is no apparent reason for this. However, we cannot
rule out a potential association between the intervention
procedure and the smaller number of patients in the
intervention group. If we assume causality, this would be
a limitation regarding the feasibility of the intervention.
Third, we did not control for continuous patient recruit-
ment by PCPs, thus cannot rule out a selection bias on
patient level. Fourth, we cannot exclude an underreport-
ing bias of clinical events, as long-term impacts of dis-
continuing drugs may sometimes require a longer time
than our follow-up of 12 months.
Conclusion
Our straight-forward and patient-centred deprescribing
procedure is effective immediately after the intervention,
but not after 6 and 12 months. Finding the ideal interval
for repetition of deprescribing interventions will allow
archiving sustainable mid and long term effects. Inte-
grating SDM in the deprescribing process is a crucial
factor for success.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12877-020-01870-8.
Additional file 1. PCP consultation checklist. Checklist PCPs of the
intervention group used as a guideline and protocol for the first
consultation. They documented all pre-interventional medication as well
as PCPs recommendation, the PCPs reason for the recommendation and
the shared-decision taken by the PCP and the patient.
Additional file 2. Baseline characteristics. Patient and PCP characteristics
at baseline, thereby comparing patients who dropped out to those who
finished the study. a) Likert scale ranging from − 2 to + 2, (− 2 the worst
possible, + 2, the best possible). b) Visual analogue scale (VAS) ranging
from 0 to 100, (0 the worst possible, 100 the best possible) c) EQ-5D-3L
scale from 1 to 5 (1 for no problems to 5 extreme or being unable to
perform a task).
Additional file 3. Drug charges in the intervention group. All drugs of
invention group patients at baseline and changes due to the invention
and during the follow-up.
Additional file 4. Deprescribing rates over time. Deprescribing rates
over time between the two groups at different time points. The
deprescribing rate was defined as the proportion of the number of drugs
stopped at a given time point in relation to the number of drugs at
baseline. N.a. = Not available.
Additional file 5. Overall drug changes during the study. All options a
drug could take during the follow-up time of 12 months. Rows 5 to 8:
pathways where drugs were stopped due to the actual intervention, + =
drugs listed at this time point, − = drugs not listed at this time point, n.a.
= not applicable. Example how to read the table: Option 5 (+/−/+/+)
shows the pathway and the number of drugs stopped due to the inter-
vention but restarted after 6 months, and still in place after 12 months.
Additional file 6. Anonymised data set. A minimal anonymised data set,
necessary to replicate our study findings. An additional data description
is included.
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